Eswar Shankar
Overview
Explore the profile of Eswar Shankar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
837
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gupta A, Choueiry F, Reardon J, Pramod N, Kulkarni A, Shankar E, et al.
bioRxiv
. 2025 Jan;
PMID: 39868332
Invasive Lobular Carcinoma (ILC), a distinct subtype of breast cancer is hallmarked by E-Cadherin loss, slow proliferation, and strong hormone receptor positivity. ILC faces significant challenges in clinical management due...
2.
Ormiston K, Kulkarni A, Sarathy G, Alsammerai S, Shankar E, Majumder S, et al.
Front Oncol
. 2024 Nov;
14:1432208.
PMID: 39525621
Triple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer with higher rates of recurrence and distant metastasis, as well as decreased 5-year survival rates. Racial...
3.
Kaur P, Shankar E, Gupta S
Cancer Lett
. 2024 Feb;
586:216706.
PMID: 38331087
Enhancer of zeste homolog 2 (EZH2) regulates gene expression and plays a definite role in cell proliferation, apoptosis, and senescence. Overexpression of EZH2 has been found in various human malignancies,...
4.
Diamantis D, Tsiailanis A, Papaemmanouil C, Nika M, Kanaki Z, Golic Grdadolnik S, et al.
J Biomol Struct Dyn
. 2023 Aug;
42(16):8638-8659.
PMID: 37639498
Elevated levels of alkaline phosphatase (ALP) in the tumor microenvironment (TME) are a hallmark of cancer progression and thus inhibition of ALP could serve as an effective approach against cancer....
5.
Atawia I, Kushwaha P, Verma S, Lin S, Shankar E, Abdel-Gawad O, et al.
Mol Carcinog
. 2023 May;
62(9):1312-1324.
PMID: 37232341
Abiraterone acetate has been clinically approved for the treatment of patients with advanced-stage prostate cancer. It reduces testosterone production by blocking the enzyme cytochrome P450 17 alpha-hydroxylase. Despite improved survival...
6.
Shankar E, Subramaniam V, Allimuthu D
Front Cell Dev Biol
. 2023 May;
11:1191682.
PMID: 37187616
No abstract available.
7.
Verma S, Kushwaha P, Shankar E, Ponsky L, Gupta S
Prostate
. 2022 Jul;
82(14):1389-1399.
PMID: 35821621
Background: Androgen deprivation therapy (ADT) is a standard treatment modality for locally advanced, high-risk, and metastatic hormone-sensitive prostate cancer. Long-term ADT treatment likely develops side-effects that include changes in cognition...
8.
Danielpour D, Corum S, Welford S, Shankar E
Curr Res Pharmacol Drug Discov
. 2022 Jan;
3:100076.
PMID: 35005610
The imidazolium compound Sepantronium Bromide (YM155) successfully promotes tumor regression in various pre-clinical models but has shown modest responses in human clinical trials. We provide evidence to support that the...
9.
Kushwaha P, Verma S, Shankar E, Lin S, Gupta S
Mol Carcinog
. 2021 Dec;
61(4):397-407.
PMID: 34939235
Enzalutamide (XTANDI®), an antiandrogen, is used for the treatment of advanced-stage prostate cancer. Approximately, 60% of patients receiving enzalutamide show initial remission followed by disease relapse with the emergence of...
10.
Verma S, Shankar E, Lin S, Singh V, Ricky Chan E, Cao S, et al.
Cancers (Basel)
. 2021 Dec;
13(23).
PMID: 34885040
Bladder cancer prognosis remains dismal due to lack of appropriate biomarkers that can predict its progression. The study aims to identify novel prognostic biomarkers associated with the progression of bladder...